Content deleted Content added
No edit summary |
JJMC89 bot III (talk | contribs) m Moving Category:4-Morpholinyl compunds to Category:4-Morpholinyl compounds per Wikipedia:Categories for discussion/Speedy |
||
(5 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
Line 13: | Line 14: | ||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = Schedule II |
| legal_CA = Schedule II |
||
| legal_DE = NpSG |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_UK = Class B |
|||
| legal_US = Schedule I |
| legal_US = Schedule I |
||
| legal_status = |
| legal_status = |
||
Line 28: | Line 30: | ||
| CAS_number_Ref = {{cascite|changed|??}} |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number = 166599-76-4 |
| CAS_number = 166599-76-4 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = J53IGM38PB |
|||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 62: | Line 66: | ||
[[Category:Aminoalkylindoles]] |
[[Category:Aminoalkylindoles]] |
||
[[Category:Naphthoylindoles]] |
[[Category:Naphthoylindoles]] |
||
[[Category: |
[[Category:4-Morpholinyl compounds]] |
||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
[[Category:CB1 receptor agonists]] |
[[Category:CB1 receptor agonists]] |
Latest revision as of 13:18, 10 July 2023
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H26N2O3 |
Molar mass | 414.505 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
JWH-198 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB1 receptor of 10 nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring.[1] It has been used mainly in molecular modelling of the cannabinoid receptors.[2][3]
In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-198 are Schedule I Controlled Substances.[4]
See also[edit]
References[edit]
- ^ Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry. 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID 15974991.
- ^ Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM (Aug 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry. 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873.
- ^ Shim JY, Collantes ER, Welsh WJ, Subramaniam B, Howlett AC, Eissenstat MA, Ward SJ (Nov 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry. 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691.
- ^ : Schedules of controlled substances